Ciprofloxacin Otic Suppliers & Bulk Manufacturers
Available Forms: Ear drops
Available Strengths: 0.2%
Reference Brands: US: Ciprofloxacin Otic (Ciloxan)
Category:
ENT
Ciprofloxacin ear drops are a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial replication. They effectively treat bacterial otitis media and external ear infections. Benefits include rapid infection control, decreased symptoms, prevention of complications, and improved ear health worldwide.
Ciprofloxacin Otic is available in Ear drops
and strengths such as 0.2%.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ciprofloxacin Otic is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ciprofloxacin Otic can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ciprofloxacin ear drops, marketed as Ciloxan, are approved in the US by the FDA and in the EU via EMA for treating bacterial ear infections. Regulatory approval requires detailed dossiers including clinical efficacy, safety data, manufacturing practices, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For dossier preparation, regulatory pathways, and market access strategies, visit PharmaTradz. Proper regional adherence supports swift approval, safe use, and global availability, enabling effective treatment for bacterial ear infections worldwide through high-quality, regionally approved ciprofloxacin ear drops.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing